Alterations in IRF1/IRF2 expression in acute myelogenous leukemia

American Journal of Hematology

Volumn 68, Issue 1, 2001, Pages 23-31

  Preisler, H D ^a   Perambakam, S ^b   Li, B ^a   Hsu, W T ^a   Venugopal, P ^a   Creech, S ^a   Sivaraman, S ^a   Tanaka, N ^c  

^a RUSH CANCER INSTITUTE   (United States)

^b TATA MEMORIAL HOSPITAL   (India)

^c NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

Acute leukemia; IRF1; IRF2

Indexed keywords

GENE PRODUCT; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 2; INTERLEUKIN 4; PROTEIN FMS; PROTEIN P53; RAS PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; LEUKEMOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW CELLS; CYTOGENETIC ANALYSIS; DNA-BINDING PROTEINS; GENES, RAS; HUMANS; INTERFERON REGULATORY FACTOR-1; INTERFERON REGULATORY FACTOR-2; INTERLEUKIN-4; LEUKEMIA, MYELOCYTIC, ACUTE; MIDDLE AGED; PHOSPHOPROTEINS; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; REFERENCE VALUES; REPRESSOR PROTEINS; RNA, MESSENGER; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034898502     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.1144     Document Type: Article

References (26)

1. Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: Retention of IRF1 on the 5q-chromosome in some patients with the 5q- syndrome
2. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia
3. Interferon regulatory factor 1 is a myeloid differentiation primary response gene induced by interleukin 6 and leukemia inhibitory factor: Role in growth inhibition
4. Interferon regulatory factor I (IRF-I) mediates cell growth inhibition by transactivation of downstream target genes
5. Anti-oncogenic and oncogenic potentials of interferon regulatory factor-1 and -2
6. Phosphorylation of the oncogenic transcription factor interferon regulatory factor 2 (IFR2) in vitro and in vivo
7. Structurally similar but functionally distinct factors, IRF-l and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes
8. Regulation of the interferon system and cell growth by the IRF transcription factors
9. Proposed revised criteria for the classification of acute myeloid leukemia
10. Fourth International Workshop in Leukemia. A prospective study of acute nonlymphocytic
11. Expression of interferon regulatory factor (IRF) genes and response to interferon-α in chronic myeloid leukaemia
12. p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes
13. Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction
14. Mutations in N-ras pre-dominate in acute myeloid leukemia
15. Analysis of N-ras gene mutations in acute myeloid leukemia by allele specific restriction analysis
16. Accuracy of histone H3 messenger RNA in situ hybridization for the assessment of cell proliferation in human tissues
17. Apoptosis in bone marrow biopsies involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes
18. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1
19. Molecular biologic studies in premyelodysplasia, myeolodysplasia, and AML
20. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
21. A hypothesis regarding the development of acute myeloid leukemia from preleukemic disorders: The role of proto-oncogenes
22. Ras mutations in patients following cytotoxic therapy for lymphoma
23. Molecular biologic studies in premyelodyspiasia, myelodysplasia, and AML
24. Suppression of c-myc or fosβ-induced cell transformation by the transcription factor IRF-1
25. Cooperation of the tumour suppressors IRF-I and p53 in response to DNA damage